Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Trop Med Hyg ; 104(6): 2238-2240, 2021 04 19.
Artigo em Inglês | MEDLINE | ID: mdl-33872213

RESUMO

Thiamine deficiency disorders are an under-recognized public health problem in low- and middle-income countries. Infantile beriberi, the most important symptom for children, is suspected to significantly contribute to infant mortality and lifelong neurodevelopmental morbidity. Lack of awareness, varied clinical presentation, and lack of a readily available diagnostic marker lead to frequent misdiagnoses. We report six thriving infants who presented with an acute fulminant illness with varied clinical manifestations mimicking common childhood illnesses like pneumonia and sepsis. Four of them presented with the severe cardiovascular form, called Shoshin beriberi, and severe pulmonary arterial hypertension. Empirical intravenous thiamine administered to four of the six infants resulted in dramatic recovery. Awareness of the clinical definition of infantile beriberi and treatment with empirical thiamine can be lifesaving.


Assuntos
Beriberi/complicações , Beriberi/diagnóstico , Deficiência de Tiamina/complicações , Beriberi/tratamento farmacológico , Beriberi/fisiopatologia , Evolução Fatal , Feminino , Humanos , Lactente , Masculino , Tiamina/administração & dosagem , Tiamina/uso terapêutico , Deficiência de Tiamina/fisiopatologia , Resultado do Tratamento
6.
Trop Doct ; 51(3): 448-450, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-33427090

RESUMO

Iron deficiency, the commonest cause of anaemia in children, is a global public health problem. Worldwide, almost 50% of children <5 years of age are anaemic. Platelet count in iron deficiency anaemia is mostly normal or high; thrombocytopenia is rare. We describe two children with iron deficiency anaemia and severe thrombocytopenia who recovered with iron supplementation alone.


Assuntos
Anemia Ferropriva , Anemia , Trombocitopenia , Anemia Ferropriva/diagnóstico , Anemia Ferropriva/tratamento farmacológico , Anemia Ferropriva/etiologia , Criança , Humanos , Ferro , Trombocitopenia/complicações
8.
Cochrane Database Syst Rev ; (5): CD005257, 2012 May 16.
Artigo em Inglês | MEDLINE | ID: mdl-22592703

RESUMO

BACKGROUND: Non-oliguric hyperkalaemia of the newborn is defined as a plasma potassium level > 6.5 mmol/L in the absence of acute renal failure. Hyperkalaemia is a common complication in the first 48 hours of life in very low birth weight (VLBW) (birth weight < 1500 g) and/or very preterm newborns (≤32 weeks gestational age). OBJECTIVES: To determine the effectiveness and safety of interventions for non-oliguric hyperkalaemia [for the purpose of this review defined as serum potassium > 6.0 mmol/L (the clinical setting in which interventions would likely be introduced prior to reaching a grossly abnormal level) and urine output > 0.5 ml/kg/hour] in preterm or VLBW infants during their first 72 hours of life. SEARCH METHODS: The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 2, 2006) was searched to identify relevant randomised and quasi-randomised controlled trials. The following data bases were searched in June 2006; MEDLINE from 1966, EMBASE from 1980, CINAHL from 1982. Search updated in June 2011. SELECTION CRITERIA: Randomised or quasi-randomised controlled trials conducted in preterm and/or VLBW neonates with a diagnosis of non-oliguric hyperkalaemia. Interventions included were those aimed at redistributing serum potassium (sodium bicarbonate or insulin and glucose) or increasing the elimination of potassium from the body [diuretics (any type) or ion exchange resins (any type), or exchange transfusion, or peritoneal dialysis, or salbutamol, or albuterol] or counteracting potential arrhythmias from hyperkalaemia (calcium) versus placebo or no intervention; or comparing any two of these interventions. Primary outcome measure was 'All cause mortality during initial hospital stay'. Secondary outcomes included common adverse outcomes seen in preterm infants. DATA COLLECTION AND ANALYSIS: We used the standard review methods of the Cochrane Neonatal Review Group. Two authors assessed all studies identified as potentially relevant by the literature search for inclusion in the review. Statistical methods included relative risk (RR), risk difference (RD), number needed to treat to benefit (NNTB) or number needed to treat to harm (NNTH) for dichotomous and weighted mean difference (WMD) for continuous outcomes reported with 95% confidence intervals (CI). We used a fixed effect model for meta-analysis. Heterogeneity was assessed using the I squared (I(2) ) statistic. MAIN RESULTS: Three randomised trials, enrolling 74 preterm infants (outcome data available on 71 infants) evaluated interventions for hyperkalaemia. Urine output was ascertained in only one study (Hu 1999). In none of the trials could we ascertain that allocation to the comparison groups was concealed. The sample sizes of the three trials were very small with 12 (Malone 1991), 19 (Singh 2002) and 40 infants enrolled (Hu 1999). The intervention and the outcome assessments could not be blinded to the clinical staff in two trials (Malone 1991; Hu 1999).One study (Malone 1991), glucose and insulin, compared to cation-exchange resin, caused a reduction in all cause mortality that was of borderline statistical significance: RR 0.18 (95% CI 0.03 to 1.15); RD -0.66 (95% CI -1.09 to -0.22); NNTB 2 (95% CI 1 to 5)]. In the study of Hu (Hu 1999), the incidence of intraventricular haemorrhage ≥ grade 2 was significantly reduced [RR 0.30 (95% CI 0.10 to 0.93); RD -0.35 (95% CI -0.62 to -0.08); NNTB 3 (95% CI 2 to 13).Albuterol inhalation versus saline inhalation changed serum K+ from baseline at four hours [WMD -0.69 mmol/L (95% CI -0.87 to -0.51)] and at eight hours [WMD -0.59 mmol/L (95% CI -0.78 to -0.40)] after initiation of treatment. No differences noted in mortality or other clinical outcomes (Singh 2002).No serious side effects were noted with either the combination of insulin and glucose or albuterol inhalation. Other interventions listed in our objectives have not been studied to date. AUTHORS' CONCLUSIONS: In view of the limited information from small studies of uncertain quality, no firm recommendations for clinical practice can be made. It appears that the combination of insulin and glucose is preferred over treatment with rectal cation-resin for hyperkalaemia in preterm infants. Both the combination of insulin and glucose and albuterol inhalation deserve further study. The two interventions could possibly be tested against each other. The effectiveness of other potentially effective interventions for non-oliguric hyperkalaemia (diuretics, exchange transfusion, peritoneal dialysis and calcium) have not been tested in randomised controlled trials.


Assuntos
Hiperpotassemia/terapia , Doenças do Prematuro/terapia , Albuterol/uso terapêutico , Glucose/uso terapêutico , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Recém-Nascido de muito Baixo Peso , Insulina/uso terapêutico , Poliestirenos/uso terapêutico , Potássio/sangue , Ensaios Clínicos Controlados Aleatórios como Assunto , Valores de Referência
10.
Acta Paediatr ; 95(1): 50-5, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16373296

RESUMO

AIM: To determine whether inferior vena cava oxygen saturation (UvO2) or lower-body fractional oxygen extraction (FOE) could detect poor cardiac output in newborns. METHODS: UvO2 and arterial oxygen saturation (SaO2) were measured simultaneously with echocardiographic determination of superior vena cava blood flow (SVC flow) at <12, 12-24 and >24 h. Haemoglobin concentration ([Hb]), haemoglobin oxygen affinity (HOA) and lactate were measured and FOE calculated. RESULTS: 56 studies in 17 infants, gestational age (median (range)) 26 wk 4 d (23 wk 2 d-42 wk 3 d): UvO2 (mean (SD)) was 84.9% (5.0), 77.6% (9.2) and 81.7% (12.9) at <12, 12-24 and >24 h, respectively; SVC flow (mean (SD)) increased from 71.7 (33) to 85 (66) and 123 (88) ml/kg/min at <12, 12-24 and >24 h, respectively. Despite a fall in mean [Hb], mean upper-body oxygen delivery increased due to increases in both SVC flow and arteriovenous content difference. There was a negative correlation between [Hb] and FOE. Infants with high HOA had significantly lower FOE. CONCLUSION: Measurement of UvO2 is feasible in newborns. Changes to SVC flow and arteriovenous content difference lead to improvements in oxygen delivery. The interaction of HOA warrants further study.


Assuntos
Baixo Débito Cardíaco/sangue , Recém-Nascido/metabolismo , Oxigênio/sangue , Oxiemoglobinas/metabolismo , Velocidade do Fluxo Sanguíneo , Débito Cardíaco/fisiologia , Baixo Débito Cardíaco/fisiopatologia , Feminino , Humanos , Recém-Nascido/fisiologia , Recém-Nascido Prematuro , Masculino , Projetos Piloto , Veia Cava Inferior , Veia Cava Superior
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...